Clinical Trial Update: A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder [Phase 3]

View source ↗

Summary

Phase 3 study evaluating a long-acting injectable risperidone for schizophrenia (and schizoaffective disorder considerations in the title) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED